Latest Breaking News On - Hase nrsn il0011809592 - Page 1 : comparemela.com

NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS - PrimeC, a novel combination therapy, demonstrated efficacy and safety in Phase IIa. | March 21, 2022

United statesUnited kingdomEuropean medicines agencyPrnewswire neurosense therapeutics ltdDrug administrationNeurosense therapeutics ltdNeurosense therapeutics receivesSense therapeuticsOrphan drug designationMassachusetts general hospitalNeuron derived exosomesNeurosense therapeutics ltd stock exchangePress releaseHase nrsn il0011809592